

17 December 2024

Treatment of Inflammatory Diseases

Gastroenterology:

With regard to the questions below, unfortunately, post encompass go live we are unable to collate this data. There is a regional meeting planned, which Pharmacy will attending to see if a solution can be found.

Previously, within Gastroenterology, the Pharmacist collated the information, as the service do not have administration staff supporting them in gathering this information and so they relied heavily on the old Pharmacy system. The service does not store this information anywhere else.

Rheumatology & Dermatology response:

1a. How many patients were treated with the following drugs, for the following diseases from the start of Jul 2024 to the end of Sept 2024? Please use the latest available 3 months if Jul to Sept is not available and specify which 3 months have been used.

Drug Name	Plaque Psoriasis	Crohn's Disease	Ulcerative Colitis	Psoriatic Arthritis	Ankylosing Spondylitis (inc. axial Spondylitis)	Rheumatoid Arthritis
Adalimumab	231					
Apremilast	7					
Bimekizumab	12					
Brodalumab	0					
Certolizumab Pegol	8					
Deucravacitinib	<5					
Etanercept	<5					
Guselkumab	91					
Infliximab (Remicade)	<5					
Infliximab (Biosimilars)	<5					
Ixekizumab	62					
Risankizumab	99					
Secukinumab	40					
Tildrakizumab	5					
Ustekinumab	71					

17 December 2024

Drug Name	Plaque Psoriasis	Crohn's Disease	Ulcerative Colitis	Psoriatic Arthritis	Ankylosing Spondylitis (inc. axial Spondylitis)	Rheumatoid Arthritis
Upadacitinib						
Vedolizumab						
Filgotinib						
Golimumab						
Mirikizumab						
Ozanimod						
Etrasimod						
Tofacitinib						
Baricitinib						
Rituximab						
Sarilumab						
Tocilizumab						

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act, as the small numbers involved could make patients personally identifiable.

Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

1b. How many patients were treated with Ustekinumab and its biosimilars from the start of Jul 2024 to the end of Sept 2024? Please use the latest available 3 months if Jul to Sept is not available and specify which 3 months has been used.

Drug Name	Plaque Psoriasis	Crohn's Disease	Ulcerative Colitis	Psoriatic Arthritis
Ustekinumab (Stelara)	71			
Ustekinumab (Pyzchiva)	0			
Ustekinumab (Uzpruvo)	0			
Ustekinumab (Wezenla)	0			